SLBT logo

SL SCIENCE HOLDING LTD

SLBTNASDAQ
πŸ† #2109 by market capUS Equity
$2.67β–² $0.00 (+0.00%)
πŸŒ™ After hours$2.67β–² 0.00%Regular close Β· extended-hours price shown
1hβ€”
24hβ–² 0.0%
7dβ–Ό 4.3%
14dβ–² 2.3%
30dβ–Ό 39.0%
1yβ–Ό 73.9%
🏦Market Cap
$1.50B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-34.7%
Declining
πŸ“ŠGross Margin
35.3%
Healthy
πŸ’΅FCF Margin
-101.5%
Thin
βš–οΈP/S Ratio
681.4x
Expensive
Otter Score
50
Weak

Trading Snapshot

Day Range
$2.64 – $2.71
52-Week Range
$2.54 – $14.50
Volume
$3.20B
Avg Volume
$2.90B
Shares Outstanding
560.8M
Next Earnings
Sep 20, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$525,874
P/E Ratio
0.0
P/S Ratio
681.4x
EPS (TTM)
$0.00
Dividend Yield
0.00%

Why Investors Own SLBT

  • βœ“High-growth profile β€” revenue up +37.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 51% gross margin and 17% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$2Mβ–² +32.6% YoY
Gross Margin (TTM)
50.6%β–² +2.4% YoY
Operating Income (TTM)
$397,702β–² +32.6% YoY
Free Cash Flow (TTM)
$380,124β–² +32.6% YoY

About SL SCIENCE HOLDING LTD

Horizon Space Acquisition II Corp. aims to achieve strategic business combinations with other companies. This objective can be fulfilled through various transactional structures, including mergers, exchanges of shares, acquisitions of assets, direct purchases of stock, recapitalizations, or other forms of corporate reorganization. The firm was founded in 2023 and maintains its headquarters in New York, New York.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
50/100

Analyst Price Target

β“˜
Average Target
$2.99
β–² +11.9% Upside
High Target$3.46
Low Target$2.68
Based on 23 analysts

Latest News & Updates

πŸš€
BenzingaΒ·1d ago

SL Science Announces Publication Of Peer-Reviewed Article In 'Biomedicines' Outlining A Rigorous Development Framework For Ξ³Ξ΄ T Cell Therapy In Glioblastoma

Glioblastoma a common and aggressive primary brain cancer in adults. Beyond reviewing existing literature, the paper outlines the specific clinical trial designs, biological measurements, and testing conditions required

BenzingaΒ·9d ago

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding (NASDAQ:SLBT)

BenzingaΒ·13d ago

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session. GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding shares is at $1.8

YahooΒ·26d ago

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (Ξ³Ξ΄) T cells in eliminating glioblastoma in preclinical studies. TAIPEI, TAIWAN, July 17, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (NASDAQ: SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, today announced its successful exhibition and participation at the 2026 World Congress of Basic and Clinical Pharma

πŸ›°οΈ
BenzingaΒ·26d ago

SL Science Presents Benefits Of Gamma Delta T Cells In Eliminating Glioblastoma In Preclinical Studies At The 2026 World Congress Of Basic And Clinical Pharmacology

SL Science Holding Limited (NASDAQ:SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, today announced its successful exhibition and

BenzingaΒ·29d ago

Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-market. Other stocks moving lower in pre-market.